Controversies & Advances in the Treatment of Cardiovascular Disease

Aug. 28, 2025 — Leading up to the European Society of Cardiology (ESC) Congress 2025, GE HealthCare introduced its latest suite of cardiology innovations designed to enhance clinical decision-making, improve workflow efficiency, and support earlier diagnosis and treatment of cardiovascular disease (CVD) — the world’s leading cause of death, responsible for an estimated 20.5 million deaths globally.i

ESC 2025 will take place Aug. 29–Sept. 1, in Madrid, Spain.

Aug. 27, 2025 – The Cardiovascular Research Foundation (CRF) has announced the late-breaking clinical trials and science that will be presented at TCT 2025, the annual scientific symposium of CRF that will take place Oct. 25–28, in San Francisco.

For more than 30 years, TCT has served as a cornerstone for advancing cardiovascular care, showcasing transformative research and fostering collaboration across disciplines. Each year, the symposium delivers pivotal data that shapes clinical practice and enhances outcomes for patients with heart and vascular disease.

Aug. 19, 2025 — Idorsia Ltd recently announced its novel dual endothelin receptor antagonist (ERA), Tryvio (aprocitentan), has been included in the new comprehensive clinical practice guidelines for the management of systemic hypertension, published by the American College of Cardiology (ACC) and the American Heart Association (AHA) Joint Committee. The updated recommendations now list Tryvio as a therapy that may be added for adults with difficult-to-control hypertension, including resistant hypertension.

Aug. 27, 2025 — Royal Philips has released Transcend Plus, the next generation of its EPIQ CVx and Affiniti CVx cardiovascular ultrasound systems. Transcend Plus delivers major advancements in image quality and artificial intelligence (AI), including newly FDA-cleared 2D and 3D image quality enhancements and a growing suite of AI-enabled clinical applications — all designed to meet the growing challenges of cardiac care.

Aug. 25, 2025 — Amgen has announced that the U.S. Food and Drug Administration (FDA) has broadened the approved use of Repatha (evolocumab) to include adults at increased risk for major adverse cardiovascular events (MACE) due to uncontrolled low-density lipoprotein cholesterol (LDL-C), commonly known as "bad cholesterol." The update removes a prior requirement for a patient to have been diagnosed with cardiovascular (CV) disease.

Aug. 25, 2025 — Merck, known as MSD outside of the United States and Canada, has announced that new clinical trial and outcomes research data will be presented at the European Society of Cardiology Congress (ESC) 2025 in Madrid, Spain, Aug. 29-Sept. 1. Data presented at ESC include Merck’s latest research focusing on atherosclerotic cardiovascular disease (ASCVD), pulmonary hypertension (PH), and heart failure with reduced ejection fraction (HFrEF).

Aug. 21, 2025 — Boston Scientific has initiated the AGENT DCB STANCE trial to assess the safety and effectiveness of the AGENT Drug-Coated Balloon (DCB) compared to the standard of care – percutaneous coronary intervention (PCI) treatment with drug-eluting stents (DES) and/or balloon angioplasty – in patients with de novo (previously untreated) coronary lesions.

Aug. 18, 2025 — (Newswise) It’s often mistaken for a heart attack, but Takotsubo cardiomyopathy — previously known as Broken Heart syndrome — is a serious and sometimes fatal heart condition increasingly reported in intensive care units (ICUs). Yet without a clear clinical pathway in ICUs, it’s often missed, putting critically ill patients at risk.

Aug. 19, 2025 — Openwater, an open-source medical technology company delivering portable, hospital-grade diagnostic and therapeutic devices, recently announced the University of Birmingham in the United Kingdom is the first to receive the latest version of Openwater’s Open-Motion device. The university’s clinical research team plans to use the technology in a new trial studying stroke rehabilitation in patients experiencing loss of movement. 

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now